Actively Recruiting
Study of PRX-115 Intravenous Infusions With or Without Methotrexate Compared to Placebo in Adults With Gout to Assess Effectiveness and Safety
Led by Protalix · Updated on 2026-09-29
150
Participants Needed
35
Research Sites
26 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the efficacy, safety, tolerability, immune response, and how the body processes PRX-115, a recombinant pegylated Uricase, in adults with gout who have difficulty lowering their serum uric acid levels with standard treatments. This phase II, randomized, double-blind, placebo-controlled study also examines the effects of combining PRX-115 with methotrexate MTX, an immunomodulator, compared to placebos. The trial aims to find the best dosing schedule for intravenous PRX-115 infusions over 24 weeks. Participants are randomly assigned to receive PRX-115 infusions intravenously on different schedules every 4 weeks for six doses, every 6 weeks for four doses, or every 8 weeks for three doses. Some groups receive PRX-115 with oral MTX at 15 mg weekly, while others receive PRX-115 with a placebo MTX or placebo infusions with placebo MTX. This parallel design allows comparison of different dosing regimens with and without MTX. The treatment period lasts 24 weeks with multiple infusions according to the assigned schedule. During the study, participants undergo regular monitoring including blood tests to measure serum uric acid levels and safety assessments. Researchers track the percentage of participants achieving serum uric acid below 6 mgdL at six months as the primary outcome, along with other time-point measurements and treatment-emergent side effects. The study includes up to 8 months of follow-up to assess safety and tolerability. Participants health status, immunogenicity, pharmacokinetics, and pharmacodynamics of PRX-115 are also evaluated throughout the trial.
CONDITIONS
Brief Title
A Study to Investigate the Clinical Effect and the Safety of PRX-115 Infused Intravenously at Different Dosing Regimens, With and Without Methotrexate, Versus Placebo in Adults Gout Patients (RELEASE)
Research Team
H
Head of Clinical Development
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here